Bandingkan Harga & Kinerja Apexindo Pratama Duta Tbk (APEX) vs UBC Medical Indonesia Tbk. (LABS)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan Apexindo Pratama Duta Tbk dan UBC Medical Indonesia Tbk.: Apexindo Pratama Duta Tbk diperdagangkan di Rp168 (kapitalisasi pasar 620,63 M, volume 24 jam 8,97 jt), sedangkan UBC Medical Indonesia Tbk. diperdagangkan di Rp165 (kapitalisasi pasar 635,95 M, volume 24 jam 843 rb). Perbedaan utamanya: Apexindo Pratama Duta Tbk dan UBC Medical Indonesia Tbk. berukuran mirip dari sisi kapitalisasi pasar, dan Apexindo Pratama Duta Tbk lebih aktif diperdagangkan (8,97 jt vs 843 rb). Mana yang lebih baik tergantung tujuan investasimu.
| APEX | LABS | |
|---|---|---|
Kapitalisasi Pasar | 620,63 M | 635,95 M |
Volume | 8,97 jt | 843 rb |
Lot | 89,74 rb | 8,43 rb |
Perputaran | 1,52 M | 137,6 jt |
Harga Rata-rata | 169,46 | 163,22 |
Nilai Transaksi | 1,52 M | 137,6 jt |
Harga Ekuilibrium Indikatif | 168 | 165 |
Volume Ekuilibrium Indikatif | 2,91 rb | 246 |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang Apexindo Pratama Duta Tbk
PT Apexindo Pratama Duta Tbk (the Company) was established based on Notarial Deed No. 115 dated June 20, 1984 of Notary Imas Fatimah, S.H. The Company belongs to a group of companiesowned by PT Aserra Capital.
Selengkapnya di halaman APEX →Tentang UBC Medical Indonesia Tbk.
PT UBC Medical Indonesia (the Company) was established under the framework of Law of the Republic of Indonesia No. 20 year 1994 concerning the Foreign Capital Investment, as amended by Law No. 25 year 2007 concerning the Capital Investment based on Notarial Deed No. 01 dated 4 June 2014 of Novita Puspitarini, S.H., Notary in Jakarta. The Company started its commercial activities in October 2014. The parent entity as well as the ultimate parent entity of the Company is PT Optel Investama Mulia.
Selengkapnya di halaman LABS →
